Marker Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: Minneapolis MN United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04511130
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Marker Therapeutics | Marker Therapeutics, Inc.